GnRH-antagonists in reproductive medicine

Archives of Gynecology and Obstetrics

Volumn 273, Issue 2, 2005, Pages 71-78

  Griesinger, Georg ^a   Felberbaum, Ricardo ^a   Diedrich, Klaus ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

Abarelix; Cetrorelix; Endometriosis; Ganirelix; GnRH antagonists; Reproductive medicine; Uterine fibroids

Indexed keywords

ABARELIX; CETRORELIX; GANIRELIX; GONADORELIN; GONADORELIN ANTAGONIST; LUTEINIZING HORMONE; PLACEBO; SEX HORMONE;

ALLERGIC REACTION; CANCER PALLIATIVE THERAPY; CLINICAL TRIAL; COMPETITIVE INHIBITION; DRUG APPROVAL; DRUG BINDING SITE; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; ENDOMETRIOSIS; GYNECOLOGIC CANCER; HEADACHE; HORMONAL THERAPY; HORMONE RELEASE; HORMONE SYNTHESIS; HOT FLUSH; HUMAN; HYPOPHYSIS FUNCTION; INFERTILITY THERAPY; LIBIDO DISORDER; OVARY HYPERSTIMULATION; PROSTATE CANCER; PROSTATE HYPERTROPHY; REPRODUCTION; REVIEW; UTERUS MYOMA; VAGINAL DRYNESS; WITHDRAWAL SYNDROME;

ENDOMETRIOSIS; ESTRADIOL; FEMALE; GONADOTROPIN-RELEASING HORMONE; HORMONE ANTAGONISTS; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; LEIOMYOMA; PITUITARY-ADRENAL SYSTEM; RECEPTORS, LHRH; UTERINE NEOPLASMS;

EID: 29144479361     PISSN: 09320067     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00404-005-0021-2     Document Type: Review

References (42)

1. Al-Inany H, Aboulghar M (2003) Gonadotrophin-releasing hormone antagonists for assisted conception (Cochrane Review). In: The Cochrane Library, Issue1. Update Software, Oxford
2. Barbieri RL (1998) Endometriosis and the estrogen threshold theory. Relation to surgical and medical treatment. J Reprod Med 43:287-292
3. Cedars MI, Lu JK, Meldrum DR, Judd HL (1990) Treatment of endometriosis with a long-acting gonadotropin-releasing hormone agonist plus medroxyprogesterone acetate. Obstet Gynecol 75:641-645
4. Compston JE, Yamaguchi K, Croucher PI, Garrahan NJ, Lindsay PC, Shaw RW (1995) The effects of gonadotrophin-releasing hormone agonists on iliac crest cancellous bone structure in women with endometriosis. Bone 16:261-267
5. Conn PM, Crowley WF (1991) Gonadotrophin-releasing hormone and its analogues. New Engl J Med 324:93-103
6. Clayton RN (1989) Gonadotrophin-releasing hormone: its actions and receptors. J Endocrinol 120:11-19
7. De Blok S, Oberye J (2001) Rapid reduction of leiomyoma volume during treatment with the GnRH-antagonist ganirelix. Gynecol Endocrinol 15:22
8. De Reijke TM, Burk K, Kurth KH (1996) Clinical and endocrinological results of patients treated with LHRH antagonist (cetrorelix). Eur Urol 30:245
9. Dlugi AM, Miller JD, Knittel J (1990) Lupron depot (leuprolide acetate for depot suspension) in the treatment of endometriosis: a randomised, placebo-controlled, double-blind study. Fertil Steril 54:419-427
10. Duijkers IJ, Klipping C, Willemsen WN, Krone D, Schneider E, Niebch G, Hermann R. (1998) Single and multiple dose pharmacokinetics and pharmacodynamics of the gonadotrophin-releasing hormone antagonist Cetrorelix in healthy female volunteers. Hum Reprod 13:2392-2398
11. Erb K, Klipping C, Duijkers I, Pechstein B, Schueler A, Hermann R (2001) Pharmacodynamic effects and plasma pharmacokinetics of single doses of cetrorelix acetate in healthy premenopausal women. Fertil Steril 75:316-323
12. Felberbaum RE, Germer U, Ludwig M, Riethmuller-Winzen H, Heise S, Buttge I, Bauer O, Reissmann T, Engel J, Diedrich K (1998) Treatment of uterine fibroids with a slow-release formulation of the gonadotrophin releasing hormone antagonist Cetrorelix. Hum Reprod 13:1660-1668
13. Felberbaum RE, Kupker W, Krapp M, Gehl B, Ludwig M, Diedrich K (2003) Preoperative reduction of uterine fibroids in only 16 days by administration of a gonadotrophin-releasing hormone antagonist (Cetrotide). Reprod Biomed Online 3:14-18
14. Felberbaum R, Kuepker W, Finas D, Krapp M, Gehl B, Altgassen C, Friedrich M, Diedrich K (2004) Uterine leiomyoma. Endocrine surgery: organ-preserving treatment options. Gynaekologische Endokrinologie 2:6-10
15. Friedman AJ (1993) Use of gonadotropin-releasing hormone agonists before myomectomy. Clin Obstet Gynecol 36:650-659
16. Garnick MB, Campion M (2000) Abarelix Depot, a GnRH antagonist, v LHRH superagonists in prostate cancer: differential effects on follicle-stimulating hormone. Abarelix Depot study group. Mol Urol 4:275-277
17. Gonzalez-Barcena D, Alvarez RB, Ochoa EP, Cornejo IC, Comaru-Schally AM, Schally AV, Engel J, Reissmann T, Riethmuller-Winzen H (1997) Treatment of uterine leiomyomas with luteinizing hormone-releasing hormone antagonist Cetrorelix. Hum Reprod 12:2028-2035
18. Hazum E, Keinan D (1985) Gonadotropin releasing hormone activation is mediated by dimerization of occupied receptors. Biochem Biophys Res Comm 133:449-456
19. Hornstein MD, Yuzpe AA, Burry KA, Heinrich LR, Buttram VL Jr, Orwoll ES (1995) Prospective randomised double-blind trial of 3 vs. 6 months of nafarelin therapy for endometriosis associated pelvic pain. Fertil Steril 63:955-962
20. Hornstein MD, Surrey ES, Weisberg GW, Casino LA (1998) Leuprolide acetate depot and hormonal add-back in endometriosis: a 12-month study. Lupron Add-Back Study Group. Obstet Gynecol 91:16-24
21. Horvath JE, Toller GL, Schally AV, Bajo AM, Groot K (2004) Effect of long-term treatment with low doses of the LHRH antagonist Cetrorelix on pituitary receptors for LHRH and gonadal axis in male and female rats. Proc Natl Acad Sci USA 101:4996-5001
22. Kiilholma P, Tuimala R, Kivinen S, Korhonen M, Hagman E (1995) Comparison of the gonadotropin-releasing hormone agonist goserelin acetate alone versus goserelin combined with estrogen-progestogen add-back therapy in the treatment of endometriosis. Fertil Steril 64:903-908
23. Kettel LM, Murphy AA, Morales AJ, Rivier J, Vale W, Yen SS (1993) Rapid regression of uterine leiomyomas in response to daily administration of gonadotropin-releasing hormone antagonist. Fertil Steril 60:642-646
24. Koch M, Steidle C, Brosman S, Centeno A, Gaylis F, Campion M, Garnick MB (2003) An open-label study of abarelix in men with symptomatic prostate cancer at risk of treatment with LHRH agonists. Urology 62:877-882
25. Kuepker W, Schultze-Mosgau A, Diedrich K (1998) Paracrine changes in the peritoneal environment of women with endometriosis. Hum Rep Update 4:719-723
26. Kupker W, Felberbaum RE, Krapp M, Schill T, Malik E, Diedrich K (2002) Use of GnRH antagonists in the treatment of endometriosis. Reprod Biomed Online 5:12-16
27. Lethaby A, Vollenhoven B, Sowter M (2002) Efficacy of pre-operative gonadotrophin hormone releasing analogues for women with uterine fibroids undergoing hysterectomy or myomectomy: a systematic review. BJOG 109:1097-1108
28. Martha PM, Gray ME, Campion M, Kuca B and Garnick MB (1999) Prolonges suppression of circulating estrogen levels without an initial hormonal flare using abarelix-depot, a pure GnRH-antagonist in women with endometriosis. Fertil Steril 72(Suppl 1):S210-(P-375)
29. McLeod D, Zinner N, Tomera K, Gleason D, Fotheringham N, Campion M, Garnick MB (2001) Abarelix Study Group. A phase 3, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancer. Urology 58:756-761
30. Nagaraja NV, Pechstein B, Erb K, Klipping C, Hermann R, Niebch G, Derendorf H (2000) Pharmacokinetic and pharmacodynamic modeling of cetrorelix, an LH-RH antagonist, after subcutaneous administration in healthy premenopausal women. Clin Pharmacol Ther 68:617-625
31. Nagaraja NV, Pechstein B, Erb K, Klipping C, Hermann R, Locher M, Derendorf H (2003) Pharmacokinetic/pharmacodynamic modeling of luteinizing hormone (LH) suppression and LH surge delay by cetrorelix after single and multiple doses in healthy premenopausal women. J Clin Pharmacol 43:243-251
32. Oberye JJ, Mannaerts BM, Kleijn HJ, Timmer CJ (1999a) Pharmacokinetic and pharmacodynamic characteristics of ganirelix (Antagon/Orgalutran). Part I. Absolute bioavailability of 0.25 mg of ganirelix after a single subcutaneous injection in healthy female volunteers. Fertil Steril 72:1001-1005
33. Oberye JJ, Mannaerts BM, Huisman JA, Timmer CJ (1999b) Pharmacokinetic and pharmacodynamic characteristics of ganirelix (Antagon/Orgalutran). Part II. Dose-proportionality and gonadotropin suppression after multiple doses of ganirelix in healthy female volunteers. Fertil Steril 72:1006-1012
34. Rein MS, Friedman AJ, Stuart JM, MacLaughlin DT (1990) Fibroid and myometrial steroid receptors in women treated with gonadotropin-releasing hormone agonist leuprolide acetate. Fertil Steril 53:1018-1023
35. Reissmann T, Felberbaum R, Diedrich K, Engel J, Comaru-Schally AM, Schally AV (1995) Development and applications of luteinizing hormone-releasing hormone antagonists in the treatment of infertility: an overview. Hum Reprod 10:1974-1981
36. Rivier J (1993) Novel antagonists of GnRH: a compendium of their physiochemical properties, activities, relative potencies and efficacy in humans. In: Lunenfeld B, Insler V (eds) GnRH analogues - the state of the art 1993. The Parthenon Publishing Group, London, pp 13
37. Smith MA, Perrin MH, Vale WW (1983) Desensitization of cultured pituitary cells to gonadotropin-releasing hormone: evidence for a post-receptor mechanism. Mol Cell Endocrinol 30:85-96
38. Surrey ES, Voigt B, Fournet N, Judd HL (1995) Prolonged gonadotropin-releasing hormone agonist treatment of symptomatic endometriosis: the role of cyclic sodium etidronate and low-dose norethindrone "add-back" therapy. Fertil Steril 63:747-755
39. Tahara M, Matsuoka T, Yokoi T, Tasaka K, Kurachi H, Murata Y (2000) Treatment of endometriosis with a decreasing dosage of a gonadotropin-releasing hormone agonist (nafarelin): a pilot study with low-dose agonist therapy ("draw-back" therapy). Fertil Steril 73:799-804
40. Tomera K, Gleason D, Gittelman M, Moseley W, Zinner N, Murdoch M, Menon M, Campion M, Garnick MB (2001) The gonadotropin-releasing hormone antagonist abarelix depot versus luteinizing hormone releasing hormone agonists leuprolide or goserelin: initial results of endocrinological and biochemical efficacies in patients with prostate cancer. J Urol 165:1585-1589
41. Wong SL, Lau DT, Baughman SA, Menchaca D, Garnick MB (2003) Pharmacokinetics and pharmacodynamics of abarelix, a gonadotropin-releasing hormone antagonist, after subcutaneous continuous infusion in patients with prostate cancer. Clin Pharmacol Ther 73:304-311
42. Yano T, Minaguchi H, Taketani Y, Mori H, Terakawa N (2001) Cetrorelix in the treatment of uterine leiomyomas. Gynecol Endocrinol 15(Suppl 1):46